Literature DB >> 8486825

Rationale and clinical indications for contrast agents in MR imaging of the brain and spine.

S W Atlas1.   

Abstract

This presentation explores clinical indications, limitations, and the scientific rationale for use of gadolinium contrast agents in MR imaging of the brain and spine. Enhancement of abnormal CNS tissues is related to structure and function of the blood-brain barrier under pathologic conditions, the prototype of which is tumor angiogenesis. Gadolinium administration can improve the diagnostic sensitivity of intracranial MR imaging, facilitating detection of leptomeningeal or ependymal disease spread and metastases. Moreover, use of contrast often provides greater diagnostic specificity by virtue of the presence and, in many cases, the absence of enhancement. This is particularly helpful in distinguishing metastases from other potential causes of high signal intensity on unenhanced spin-echo (SE) images. In addition to improving diagnosis of neoplasia, gadolinium use is often necessary to demonstrate most cranial neuropathies and to differentiate herniated disc from epidural fibrosis in the failed-back surgery syndrome. Advanced techniques that exploit gadolinium's properties (e.g., MR angiography, perfusion MR imaging) or increase its diagnostic effectiveness (e.g., fat suppression in the postoperative spine) are treated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486825     DOI: 10.1097/00004728-199301001-00001

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  1 in total

1.  Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.

Authors:  Cesare Colosimo; Philippe Demaerel; Paolo Tortori-Donati; Catherine Christophe; Mark Van Buchem; Barry Högström; Gianpaolo Pirovano; Ningyan Shen; Miles A Kirchin; Alberto Spinazzi
Journal:  Pediatr Radiol       Date:  2005-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.